MASI Masimo Corporation : Bullish and Bearish Analyst Opinions

Danaher (DHR) agreed to buy Masimo (MASI) for $80/share, a 40% premium. The move has already happened (stock up 34%). This is now a merger arbitrage situation. The massive premium validates the valuation of medical tech assets but leaves little upside for new entrants unless a bidding war emerges. NEUTRAL. The easy money has been made on the announcement. Regulatory hurdles block the deal (downside risk).

Activist activity is surging. Elliott has a >10% stake in Norwegian Cruise Line (NCLH). Starboard is pushing TripAdvisor (TRIP) for a sale. Jana Partners is in Pfizer (PFE). Danaher (DHR) is acquiring Masimo (MASI). Activists (Elliott, Starboard) are aggressively pushing for immediate value unlocking via sales, splits, or operational overhauls. This historically creates a floor for the stock price and drives short-term upside as the market prices in M&A premiums. Long the activist targets (NCLH, TRIP, MASI). Deal talks fail; activists exit without forcing change.

"ZIM shipping up a whopping 40% on the back of some M&A news... Danaher nearing a $10 billion deal for Masimo... Norwegian Cruise is up on the back of activist investor Elliott taking a stake... Paramount... renewed talks with Warner Bros." We are in a high-velocity M&A environment. ZIM and MASI are direct buyout targets with immediate premiums. NCLH is an activist turnaround play (Elliott usually forces operational improvements or a sale). PARA is in a bidding war (Warner vs. Netflix), which typically drives the price to the highest bidder. LONG these specific tickers as event-driven plays. Regulatory blocking of deals (antitrust) or deal financing falling through.

"The FT is reporting Danaher is nearing an almost $10 billion deal for medical technology company Masimo." When a specific acquisition price or deal is reported as "nearing," the target company's stock usually jumps to trade near the acquisition premium. LONG as an M&A arbitrage play (assuming the deal hasn't fully priced in yet). Regulatory hurdles could block the deal; deal talks could fall apart.